Rahul Banerjee: Chronicle disparities in Relapsed or Refractory myeloma and why they matter

Rahul Banerjee shared on X:

“Now in Blood Cancer Journal – our work to chronicle disparities specifically in Relapsed or Refractory myeloma and why they matter.

Trial-studied vs optimal drug dosing
Racial and socioeconomic gaps re: CAR-T and bsAbs
Multiple Myeloma supportive care, inc PCP access, and more

Disparities are well documented in myeloma, particularly re: diagnosis, time to Treatments initiation, access to ASCT. But many unique factors arise at relapse that make the landscape of great R/R Multiple Myeloma treatment options harder to traverse for some patients than others. Examples below.

One problem to highlight: The stubborn disconnect between drug dosing in initial trials vs optimized strategies we’ve discovered thereafter to high PFS and low tox. Not just myeloma trivia for fellows… important to ensure there aren’t 2 standards of care for Multiple Myeloma treatment.

 

Limitations of our review include emphasis on USA patients living with myeloma, when in reality the biggest gaps between ‘haves’ and ‘have-nots’ in MM fall across international lines. And other disparities: language status, caregiver status, and intersectionality of them all.

Thanks Blood Cancer Journal and reviewers for excellent feedback and i3 Health for convening our interdisciplinary task force.

I learned so much from Craig Cole, Beth Faiman, Shonali Midha, Sikander Ailawadhi and of course the inimitable Yelak Biru who helped ground us all!”

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

Authors: Rahul Banerjee, Yelak Biru, Craig E. Cole, Beth Faiman, Shonali Midha and Sikander Ailawadhi 

Source: Rahul Banerjee/X

For more posts by Rahul Banerjee, visit oncodaily.com

Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in haematology and oncology from University of California, San Francisco. He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.